Related references
Note: Only part of the references are listed.Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Interference of STAT 5b expression enhances the chemo-sensitivity of gastric cancer cells to gefitinib by promoting mitochondrial pathway-mediated cell apoptosis
Tao Sun et al.
ONCOLOGY REPORTS (2015)
Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib
Jin-An Ma et al.
MOLECULAR MEDICINE REPORTS (2015)
Differential Transcriptional Effects of EGFR Inhibitors
Miroslav Blumenberg
PLOS ONE (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Evaluation of the Antitumor Effects and Mechanisms of PF00299804, a Pan-HER Inhibitor, Alone or in Combination with Chemotherapy or Targeted Agents in Gastric Cancer
Hyun-Jin Nam et al.
MOLECULAR CANCER THERAPEUTICS (2012)
A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus
David H. Ilson et al.
CANCER (2011)
Anti-HER agents in gastric cancer: from bench to bedside
Lorenzo Fornaro et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
Critical appraisal of trastuzumab in treatment of advanced stomach cancer
Judith Meza-Junco et al.
Cancer Management and Research (2011)
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
Mark E. Davis et al.
NATURE (2010)
Trastuzumab-induced HER Reprogramming in Resistant Breast Carcinoma Cells
Murli Narayan et al.
CANCER RESEARCH (2009)
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells
Young-Kwang Yoon et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity
M. Scaltriti et al.
ONCOGENE (2009)
EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number
M. A. Kim et al.
HISTOPATHOLOGY (2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer
David Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
Modeling oncogene addiction using RNA interference
S. Michael Rothenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A phase II study of gefitinib monotherapy in advanced Esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response
David R. Ferry et al.
CLINICAL CANCER RESEARCH (2007)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive untethered EGFR dimers - Implications for combination therapy with monoclonal antibody 806
Hui K. Gan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis
H. Yokoyama et al.
BRITISH JOURNAL OF CANCER (2006)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
Federico Rojo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients
ML Janmaat et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Reorganization of ErbB family and cell survival signaling after knock-down of ErbB2 in colon cancer cells
YP Hu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
ERBB receptors and cancer: The complexity of targeted inhibitors
NE Hynes et al.
NATURE REVIEWS CANCER (2005)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
W Pao et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Future options with trastuzumab for primary systemic and adjuvant therapy
J Baselga et al.
SEMINARS IN ONCOLOGY (2004)
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment
N Normanno et al.
ENDOCRINE-RELATED CANCER (2003)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
